The Beacon

https://is1-ssl.mzstatic.com/image/thumb/Podcasts115/v4/57/fc/1d/57fc1d78-2291-cddd-3615-62d082ea77d2/mza_7454424351578478871.png/600x600bb.jpg

The Beacon

H. Jack West, MD

74 episodes

1 month ago

Dr. Jack West reviews emerging new information and controversial topics in health care in general, cancer treatment in particular.

Medicine

Health & Fitness

RSS

All content for The Beacon is the property of H. Jack West, MD and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Dr. Jack West reviews emerging new information and controversial topics in health care in general, cancer treatment in particular.

Medicine

Health & Fitness

Episodes (20/74)

The Beacon

Dr. David Spigel, Part 2: Identifying the Optimal Duration for Immunotherapy in Responding Patients with Advanced Lung Cancer (BMIC-075)

6 years ago

20 minutes 37 seconds

The Beacon

Dr. David Spigel, Part 1: Clinical Research and the Growing Complexity of Cancer Care in a Community Setting (BMIC-074)

6 years ago

24 minutes 33 seconds

The Beacon

Top 5 Most Influential Trial Findings in Lung Cancer Management in 2018 (BMIC-073)

6 years ago

13 minutes 41 seconds

The Beacon

What does the CheckMate-331 trial of nivolumab vs. chemo for relapsed SCLC tell us? (BMIC-072)

6 years ago

9 minutes 10 seconds

The Beacon

The IMpower130 Trial of Carbo/Nab-Paclitaxel +/- Atezolizumab: Does this Positive Trial Change Management? (BMIC-071)

6 years ago

10 minutes 10 seconds

The Beacon

Overall Survival Benefit for Local Ablative Therapy as Consolidation for Oligometastatic Stage IV NSCLC: Where Does it Fit in Practice Now? (BMIC-070)

6 years ago

10 minutes 5 seconds

The Beacon

The IMpower132 Trial: Does This Change the Advanced NSCLC Landscape? (BMIC-069)

6 years ago

6 minutes 51 seconds

The Beacon

The MYSTIC Trial has Failed on Overall Survival in Advanced NSCLC: What Does and Doesn't This Tell Us? (BMIC-068)

6 years ago

9 minutes 55 seconds

The Beacon

Pembrolizumab for Patients with Advanced NSCLC and a Performance Status (PS) of 2: Results of the PePS2 Trial (BMIC-067)

6 years ago

4 minutes 25 seconds

The Beacon

Long-Term Management of Patients Doing Well on Immunotherapy for Advanced NSCLC: Insights from KEYNOTE-010 (BMIC-066)

6 years ago

8 minutes 15 seconds

The Beacon

Updated Results on PACIFIC Trial: Should we Revise Who Should Receive Consolidation Immunotherapy after Chemo/Radiation? (BMIC-065)

7 years ago

7 minutes 34 seconds

The Beacon

IMpower133: Is there Finally a New Standard of Care for Extensive Stage SCLC? (BMIC-064)

7 years ago

7 minutes 31 seconds

The Beacon

"Best Treatment First": Implications for front-Loading Combinations in Lung Cancer (BMIC-063)

7 years ago

9 minutes 21 seconds

The Beacon

Local Therapy for Advanced NSCLC: Revising Outdated Principles for Selected Patients (BMIC-062)

7 years ago

15 minutes 49 seconds

The Beacon

TIP or BEP for Intermediate or Poor Risk Testicular Cancer?: Highlights in GU Oncology from ASCO 2018 (BMIC-061)

7 years ago

3 minutes 52 seconds

The Beacon

Adjuvant Docetaxel for Intermediate or High Risk Prostate Cancer After Radiation: Highlights in GU Oncology from ASCO 2018 (BMIC-060)

7 years ago

1 minute 48 seconds

The Beacon

What is Positive Predictive Value of PET PSMA in Biochemical Recurrence of Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-059)

7 years ago

2 minutes 59 seconds

The Beacon

New Data & Context for a PARP Inhibitor/Abiraterone Combination in Metastatic Prostate Cancer: Highlights in GU Oncology from ASCO 2018 (BMIC-058)

7 years ago

3 minutes 15 seconds

The Beacon

Is PROSTVAC the Vaccine Therapy We've Been Waiting for in Advanced Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-057)

7 years ago

2 minutes 16 seconds

The Beacon

Is More Better with Radium-223 for Metastatic Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-056)

7 years ago

1 minute 21 seconds